GSK beat expectations on revenue and earnings in the first quarter, despite a drop in sales of the Covid-19 treatment Xevudy after the US regulator said it was unable to tackle the most prevalent variants of the virus.
Total sales fell 8 per cent at constant exchange rates to £7 billion (€7.9 billion), against expectations of £6.5 billion. Excluding sales related to Covid-19, revenues rose 10 per cent to £6.8 billion, driven by sales of HIV medicines and a vaccine for shingles.
Operating profit was down 15 per cent to £2.1 billion, partly because of comparison with the first quarter last year, when GSK received extra money from a one-off legal settlement with Gilead. Adjusted earnings per share were 37p, above the consensus forecast for 33.2p.
Emma Walmsley, GSK’s chief executive, said the company had made a “strong start to 2023″, with significant approvals and clinical trial results to come.
Stealth sackings: why do employers fire staff for minor misdemeanours?
How much of a threat is Donald Trump to the Irish economy?
MenoPal app offers proactive support to women going through menopause
Ezviz RE4 Plus review: Efficient budget robot cleaner but can suffer from wanderlust under the wrong conditions
“We are very focused on our upcoming launches, including our potential RSV [respiratory syncytial virus] older adult vaccine, and on continuing to strengthen our pipeline,” she said.
Earlier this month, GSK agreed to buy Canadian biotech Bellus Health in a $2 billion (€1.8 billion) deal, adding a speciality medicine aimed at the 10 million people who suffer from a debilitating and persistent cough. Last year, GSK also made a $1.9 billion acquisition of Sierra Oncology and agreed a deal worth up to $3.3 billion for vaccine maker Affinivax.
In a media call on Wednesday, Ms Walmsley called on the UK government to invest in technology to make the most of the “unique opportunity” of data held by the NHS and address a dramatic drop in clinical trials.
She added that the UK was at a “tipping point” in its relationship with the life sciences sector, which has been battling the government over taxes on drug prices, and what it says is a lack of investment in innovation. The number of industry clinical trials in the UK has fallen 41 per cent since 2017.
GSK maintained its full-year guidance, forecasting turnover to increase between 6 and 8 per cent, and a 12 to 15 per cent rise in adjusted earnings per share. The guidance is at constant exchange rates and excludes sales related to Covid-19. GSK declared a dividend of 14p, with 56.5p expected for the full year 2023.
During the quarter, a London court found that GSK owed royalties to AstraZeneca for all of its sales of its Zejula cancer drug, rather than just a proportion of them, including back sales. But it has not yet decided how much GSK will owe. On Wednesday, GSK said it is considering an appeal.
Separately on Wednesday, Swiss pharmaceutical company Roche said first-quarter sales fell 7 per cent to 15.32 billion Swiss francs, driven by much lower demand for Covid-19 tests. Roche had previously warned this would be the case.
Sales from its pharmaceuticals division grew 5 per cent to ChF11.7 billion in the same period, driven by newer medicines. Eye drug Vabysmo, launched a year ago, was the biggest growth driver, Roche said.
Roche shares fell 1.3 per cent in early trading, while AstraZeneca was down 1.7 per cent by midmorning. – Copyright The Financial Times Limited 2023
